Skip to content

MAXCYTE, INC. (MXCT) — Institutional Holders & Catalysts | BiotechEdge

BiotechEdgeNew: AI Alerts

Catalysts Convergence Squeeze Signals Cash Runway Insiders Research

Sign In Start 14-Day Free Trial

Home›Companies›MAXCYTE, INC. (MXCT)

MAXCYTE, INC.

MXCT

Held by 1 specialist biotech fund

1 fund opened new positions. Short interest: 5.2% of float.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

1.5/10

1 fund opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Deerfield Management

AI Signal

SIGNAL NOTE: Deerfield Exit from MXCT

Deerfield's complete exit from Maxcyte signals confidence loss ahead of potential near-term catalysts in the CAR-T cell therapy space. Maxcyte's pipeline relies heavily on its cell engineering platform for autologous/allogeneic therapies, but the exit suggests concern over clinical readout timing, competitive pressure from Gilead/Juno, or insufficient differentiation to justify position risk.

Unlock full AI analysis — 14-day free trial

Position Trend

May 15, 2025

$52K

1 fund

Aug 14, 2025

$0

0 funds

Nov 14, 2025

$0

0 funds

Feb 17, 2026

$0

0 funds

-100% total institutional value over 4 quarters

Short Interest

Short Shares

5.49M

Change

+7.8%

Days to Cover

4.7

% of Float

5.2%

Settlement

Mar 13, 2026

Short interest over 2 periods

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ACasdin Capital0.0%Feb 14, 2024

SC 13G/ACasdin Capital9.0%Jan 10, 2023

SC 13GCasdin Capital14.2%Aug 3, 2021

Position Details

Deerfield ManagementEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

3 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

CPRX1 fund RXST1 fund GPCR1 fund SGRY1 fund TNGX1 fund TRUP1 fund VERA1 fund RDNT1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: